Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corifollitropin alfa + menotropin is a combination therapy used in controlled ovarian stimulation protocols, particularly for poor ovarian responders. Corifollitropin alfa is a long-acting recombinant follicle stimulating hormone (FSH) analog that can sustain follicular growth for seven days with a single injection, replacing the need for daily FSH injections. Menotropin (highly purified human menopausal gonadotropin or hpHMG) is then added to provide additional gonadotropin support. This combination is used in a GnRH antagonist protocol for women undergoing assisted reproductive technologies. Clinical studies have shown promising results in young poor ovarian responders (<40 years) with ongoing pregnancy rates of approximately 28%.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corifollitropin alfa + menotropin.